Considering that CLL is predominantly a disease of the elderly and the increasing cost of new drugs (45), the validation of predictive bio- markers represents a necessary step to allow clinicians to design a sus- tainable treatment strategy, giving the patients the highest probability of achieving a durable response with a real benefit in terms of quality of life. It is therefore anticipated that predictive biomarkers will have an increasingly important role to foster translation of trial results into reality.
GENETIC-BASED RISK STRATIFICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA: IS IT STILL USEFUL?
F. M. Quaglia;
2019-01-01
Abstract
Considering that CLL is predominantly a disease of the elderly and the increasing cost of new drugs (45), the validation of predictive bio- markers represents a necessary step to allow clinicians to design a sus- tainable treatment strategy, giving the patients the highest probability of achieving a durable response with a real benefit in terms of quality of life. It is therefore anticipated that predictive biomarkers will have an increasingly important role to foster translation of trial results into reality.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
